Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Palestine Politics Today.
Press releases published on July 15, 2025
Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report – Hagens Berman
SAN FRANCISCO, July 15, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (NASDAQ: ABL) is under mounting pressure as its stock continues to slide, driven by a series of damning reports from Morpheus Research—a newly formed investigative group led by …
Corporations Unite in Action to Support America’s Youth
ATLANTA, July 15, 2025 (GLOBE NEWSWIRE) -- As the back-to-school season approaches, parents and caregivers nationwide are grappling with concerns about academic recovery and youth mental health. Yet, a staggering challenge looms: 25 million students lack …
MOTHERS SELECT GRASSROOTS PROJECTS FOR GRANTS
Kansas City, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- For the first time in its history, the international nonprofit Unbound has empowered a collective of mothers in Africa, Asia and Latin America who are participating in the Unbound program to review and …
ZenaTech to Accelerate ZenaDrone Manufacturing for US Defense and Commercial Drones Following Recent One Big Beautiful Bill, Executive Orders, and Secretary of Defense Policy Directives
VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), …
Maryland Supreme Court Affirms MSP Recovery’s Assignments, Paving the Way for Class Action Lawsuit Against GEICO
MIAMI, July 15, 2025 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. (NASDAQ: MSPR) (“MSP Recovery” or the “Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, announces a major legal victory before the …
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology Preclinical candidate data expected in early 2026, with …